Clinical Trial Update: An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing BMS-986205 combined with nivolumab vs nivolumab alone in advanced melanoma completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• BMS-986205 (BMS-986205)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma, Skin Cancer | Phase 3 | Status: COMPLETED | Results posted: 2021-07-09